
|Videos|May 31, 2023
The Future of NDMM: Ongoing Studies and Current Challenges in the Landscape
Author(s)Melissa Alsina, MD
Melissa Alsina, MD cites recent data from ongoing studies as well as highlights remaining questions and unmet needs in the NDMM landscape.
Advertisement
Episodes in this series

Case: A 77-Year-Old Man with Transplant-Not Preferred Newly Diagnosed Multiple Myeloma (NDMM)
Patient KR is a 77 y/o man.
- PMH: T2DM, hypertension, and COPD
- SMH: Does not smoke; drinks occasionally in social settings.
Clinical Presentation:
- In January 2023, KR visited his PCP for his annual checkup. He reported having persistent bone pain and increased fatigue.
Clinical Workup and Diagnosis:
- Calcium 12.5 mg/dL
- CrCl, 40 mL/min
- Hgb, 9.8 g/dL
- β-2 microglobulin, 7.8 mg/L
- Albumin, 3.4 g/dL
- LDH wnl
- sFLC lambda at diagnosis, 1700 mg/L
- Bone marrow showed 40% clonal plasma cells LLC restricted-Clonose Id obtained.
- del(17p) abnormality detected by FISH.
- PET-CT showed osteolytic lesions in several ribs; no extramedullary disease (EMD).
- ECOG PS 2
- IMWG Frailty Status: Intermediate-Frail
- KR was diagnosed with ISS III/R-ISS stage III lambda LC multiple myeloma; determined to be transplant-not preferred based on age and comorbidities.
Current Treatment:
- After discussions with his family and clinical team, KR was initiated on Daratumumab/lenalidomide/dexamethasone (D-Rd).
- Patient achieved complete response (CR).
Advertisement
Related to this article

Updated LEGEND trial data show durable responses with detalimogene in BCG-unresponsive NMIBC, supporting a planned BLA submission by year-end 2026.

The FDA issued a complete response letter to the biologics license application for ivonescimab for use in combination with chemotherapy in EGFR-mutated NSCLC.

Crossover to bezuclastinib plus sunitinib after progression on sunitinib improved PFS and responses in GIST in phase 3 PEAK, with no new safety signals.

Arvind Dasari, MD, MS, explains how to sequence radioligand therapy, cabozantinib, and everolimus in well-differentiated neuroendocrine tumors.

A survey of US veterans with non-muscle invasive bladder cancer identifies barriers to treatment access, care coordination challenges, and gaps in patient education.

The perioperative regimen improved event-free and overall survival in the phase 3 VOLGA trial, offering a new option for patients with muscle-invasive bladder cancer who cannot receive or decline cisplatin.

Ravi Parikh, MD, MPP, discusses the future of oncology practice, including real-world data, patient engagement, emerging technologies, and policy priorities shaping cancer care.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Does Not Approve Ivonescimab for EGFR-Mutant NSCLC
2
Dr Dasari on Sequencing RLT, Cabozantinib, and Everolimus in NETs
3
Crossover to Bezuclastinib Plus Sunitinib Improves Disease Control in Pretreated GIST
4
FDA Approves Durvalumab-EV Combo, Expanding MIBC Treatment Options
5
